CD274 and non-small cell lung carcinoma: ICIs, mainly monoclonal antibodies blocking PD‐1 and its ligand PD‐L1, have revolutionized the therapeutic landscape for NSCLC, particularly in the locally advanced (stage III) and metastatic (stage IV) settings.19